Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sanofi-Aventis ends deal with AEterna Zentaris following failure of cetrorelix

This article was originally published in Scrip

Executive Summary

Sanofi-Aventis and AEterna Zentaris have ended their US development deal for the luteinising hormone-releasing hormone (LHRH) cetrorelix after the product failed to reach its primary endpoint in European Phase III trial results announced earlier this month (scripnews.com, December 16th, 2009).

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC006155

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel